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1. DNA test based on analysis 
of 3020insC in NOD2 gene
3020insC in the NOD2 gene increases the risk of:
• breast cancer DCIS below age 50 about 5-fold – this
mutation is detected in 8% of all breast cancer cases,
• colorectal cancer approximately 2-fold above age
60 – this mutation is present in 15% of all colorectal
cancer cases,
• lung cancer about 2-fold – this mutation is present
in 12% of all lung cancer cases,
• ovarian cancer about 1.5-fold – this mutation is
present in 11% of all ovarian cancer cases [1, 2].
Surveillance for carriers of 3020insC in NOD2
gene recommended as an option:
Recommendations for women:
• breast self-examination,
• breast examination by doctor from age 20, 1 × 6
months,
• breast USG from age 20, 1 × year,
• mammography from age 35, 1 × year, alternately
with breast USG,
• intravaginal USG from age 45, 1 × year,
• colonoscopy or barium enema age 60, every 5 years
or more often in case of intestinal abnormalities,
• smoking forbidden, diet richer in fruits and vegetables.
Recommendations for men:
• colonoscopy or barium enema age 60, every 5 years
or more often in case of any intestinal abnormalities,
• smoking forbidden, diet richer in fruits and vegetables.
2. DNA test based on analysis of 1100delC,
IVS2+1G>A, del5395, I157T mutations
in CHEK2 gene
CHEK2 protein truncating mutations (1100delC,
IVS2+1G>A, del5395) increase the risk of:
• breast cancer about 2.4-fold – these mutations
are present in about 2.5% of all breast cancer
cases,
• prostate cancer about 2.3-fold – these mutations are
present in about 2.5% of all prostate cancer cases
and about 5% of familial prostate cancer cases; the
risk is increased about 5-fold if prostate cancer is
present in at least one first degree relative,
• papillary thyroid cancer – about 5-fold – these
mutations are present in about 4% of all papillary
thyroid cancer cases [3-5].
Missense mutation I157T in the CHEK2 gene
increases the risk of:
• breast cancer (more commonly lobular subtype)
about 1.5-fold – this mutation is present in about 7%
of all breast cancer cases,
• prostate cancer about 1.6-fold – this mutation is
present in about 8% of all prostate cancer cases and
about 12% of familial prostate cancer cases; the risk
is increased about 3-fold if prostate cancer is present
in at least one first degree relative,
• papillary thyroid cancer – about 2-fold – this mutation
is present in about 9% of all papillary thyroid cancer
cases,
• kidney cancer – about 2-fold – this mutation is
present in about 10% of all kidney cancer cases,
• colorectal cancer – about 2-fold – this mutation is
present in about 10% of colorectal cancer cases 
[2-4],
• ovarian cancer of low-grade about 2-fold – this
mutation is present in about 10% of ovarian cancer
cases G1; and ovarian epithelial tumours of
borderline malignancy about 2.5-fold – this mutation
is present in about 11.5% of ovarian cancer cases
of borderline malignancy [6].
Surveillance for carriers of protein truncating
mutations of CHEK2 (1100delC, IVS2+1G>A,
del5395) recommended as an option:
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Recommendations for women:
• breast self-examination,
• breast examination by doctor from age 25, 1 × 6
months,
• breast USG from age 25, 1 × year,
• mammography from age 35, 1 × year, alternately
with breast USG,
• thyroid USG from age 20, 1 × year.
Recommendations for men:
• digital rectal examination of prostate, PSA from age
50, 1 × year,
• consideration of saturation biopsy of prostate after
age 60 – in case of a positive family history of
prostate cancer in a first degree relative.
Surveillance for carriers of CHEK2 I157T missense
mutation recommended as an option:
Recommendations for women:
• breast self-examination,
• breast examination by doctor from age 40, 1 × 6
months,
• breast USG from age 40, 1 × year,
• MRI or mammography from age 40, 1 × year,
alternately with breast USG,
• intravaginal USG from age 25, 1 × year,
• abdominal USG from age 40, 1 × year,
• colonoscopy or barium enema  from age 60, every
5 years or more often in case of intestinal
abnormalities,
• thyroid USG from age 20, 1 × year.
Recommendations for men:
• abdominal USG from age 40, 1 × year,
• colonoscopy or barium enema from age 60, every
5 years or more often in case of intestinal
abnormalities,
• digital rectal examination of prostate, PSA from age
50, 1 × year,
• consideration of saturation biopsy of prostate after
age 60 – in case of a positive family history of
prostate cancer in a first degree relative.
3. DNA test based on analysis of 657del5
mutation in NBS1 gene
Mutation 657del5 in the NBS1 gene increases the
risk of:
• breast cancer about 2-fold – this mutation is present
in about 1% of all breast cancer cases,
• prostate cancer about 4-fold – this mutation is
present in about 3% of all prostate cancer cases and
about 9% of familial prostate cancer cases; the risk
is increased about 15-fold if prostate cancer is
present in at least one first degree relative [7].
Surveillance for carriers of NBS1 657del5 mutation
recommended as an option:
Recommendations for women:
• breast self-examination,
• breast examination by doctor from age 30, 1 × 6
months,
• breast USG from age 30, 1 × year,
• mammography from age 30, 1 × year, alternately
with breast USG.
Recommendations for men:
• digital rectal examination of prostate, PSA from age
50, 1 × year,
• consideration of saturation biopsy of prostate after
age 60 – in case of a positive family history of
prostate cancer in a first degree relative.
4. DNA test based on analysis of A148T
variant of CDKN2A (p16) gene
A148T in the CDKN2A gene increases the risk of: 
• malignant melanoma – about 2-fold – this mutation
is present in about 7% of all melanoma cases,
• breast cancer (more commonly DCIS) about 1.5-fold
– this mutation is present in about 5% of all breast
cancer cases,
• colorectal cancer – about 1.5-fold – this mutation
is present in about 5% of all colorectal cancer
cases,
• lung cancer – about 2-fold – this mutation is present
in about 7% of all lung cancer cases [8-10].
Surveillance for carriers of CDKN2A A148T
mutation recommended as an option:
Recommendations for women:
• breast self-examination,
• breast examination by doctor from age 20, 1 × 6
months,
• breast USG from age 20, 1 × year,
• mammography from age 35, 1 × year, alternately
with breast USG,
• colonoscopy or barium enema from age 60, every
5 years or more often in case of intestinal
abnormalities,
• smoking forbidden, diet rich in fruits and vegetables,
• the use of high sun protection factor sunscreens
(30 or more), avoidance of physical trauma of nevi,
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• in cases with moles showing clinical signs of
malignant transformation (increase of size, red hue,
bleeding, pruritus) immediate consultation by
dermatologist or oncologist.
Recommendations for men:
• colonoscopy or barium enema from age 60, every
5 years or more often in case of intestinal
abnormalities,
• smoking forbidden, diet rich in fruits and vegetables,
• the use of high sun protection factor sunscreens 
(30 or more), avoidance of physical trauma of nevi,
• in cases with moles showing clinical signs of
malignant transformation (increase of size, red hue,
bleeding, pruritus) immediate consultation by
dermatologist or oncologist.
5. DNA test based on analysis of variants
C142G, G355T, G4326C of CYP1B1
gene
Homozygous carriers of variants C142G, G355T,
G4326C (homozygotes GTC) of the CYP1B1 gene are
at 2-fold increased risk of breast cancer. This genotype
is present in about 12% of breast cancer cases [11].
Surveillance recommended as an option for women
with homozygous GTC genotype in CYP1B1 gene:
• breast self-examination,
• breast examination by doctor from age 25, 1 × 6
months,
• breast USG from age 25, 1 × year,
• MRI or mammography from age 25-30, 1 × year,
alternately with breast USG.
6. DNA test based on analysis of C5972T
variant of BRCA2 gene 
C5972T variant in the BRCA2 gene increases the
risk of breast cancer with DCIS below age 50 about
3-fold; homozygous carriers of this variant
(homozygotes TT) are at about 5-fold increased risk of
breast cancer below age 50; this variant is present in
about 6% of breast cancer cases below age 50 [12].
Surveillance recommended as an option for carriers
of C5972T variant:
• breast self-examination,
• breast examination by doctor from age 25, 1 × 6
months,
• breast USG from age 25, 1 × year,
• mammography from age 35, 1 × year, alternately
with breast USG.
7. DNA test based on analysis of C61G
and 4153delA mutations in BRCA1
gene in men
C61G and 4153delA mutations in the BRCA1 gene
increase the risk of prostate cancer about 3.6-fold –
these mutations are present in about 0.4% of all
prostate cancer cases; the risk is increased about 
12-fold if prostate cancer is present in at least one first
degree relative [13].
Surveillance recommended as an option for men
with C61G or 4153delA mutation:
• digital rectal examination of prostate, PSA from age
50, 1 × year,
• consideration of saturation biopsy of prostate after
age 60 – in case of a positive family history of
prostate cancer in a first degree relative.
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